Frontiers in Medical Science Research, 2025, 7(4); doi: 10.25236/FMSR.2025.070403.
Yuli Bao1, Linyong Du2
1College of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China
2Key Laboratory of Laboratory Medicine, Ministry of Education, College of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
Seven elongases (ELOVL1-7) exist within the human body, exhibiting distinct tissue expression patterns and substrate specificities. ELOVL1 serves as the primary rate-limiting enzyme for the synthesis of very long-chain fatty acids (VLCFAs), regulating the rate and direction of this metabolic process. Accumulating research demonstrates a close association between ELOVL1 and tumorigenesis and progression; however, its specific function in glioma remains incompletely understood. In this study, we utilized data from The Cancer Genome Atlas (TCGA), the Genotype-Tissue Expression (GTEx) database, and the Chinese Glioma Genome Atlas (CGGA) to investigate the association between ELOVL1 expression and the clinicopathological/molecular characteristics of glioma patients, as well as its correlation with patient prognosis. Our findings reveal that high ELOVL1 expression is significantly associated with poor patient prognosis. Further analysis of the biological role of ELOVL1 in glioma indicates its involvement in multiple biological processes implicated in glioma development, including immune responses, inflammatory responses, and the regulation of defense responses within the immune system. Immune infiltration analysis using the CIBERSORT database uncovered correlations between high ELOVL1 expression and the infiltration of various immune cell types, as well as immune checkpoints, in glioma. In summary, ELOVL1 may serve as a promising potential biomarker for the clinical diagnosis and treatment of glioma.
ELOVL1, Glioma, Immune, Prognosis
Yuli Bao, Linyong Du. ELOVL1 as a Potential Biomarker Associated with Poor Prognosis in Glioma. Frontiers in Medical Science Research (2025), Vol. 7, Issue 4: 22-29. https://doi.org/10.25236/FMSR.2025.070403.
[1] LOUIS D N, PERRY A, WESSELING P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary [J]. Neuro Oncol, 2021, 23(8): 1231-51.
[2] DARLIX A, ZOUAOUI S, RIGAU V, et al. Epidemiology for primary brain tumors: a nationwide population-based study [J]. J Neurooncol, 2017, 131(3): 525-46.
[3] TYKOCKI T, ELTAYEB M. Ten-year survival in glioblastoma. A systematic review [J]. J Clin Neurosci, 2018, 54: 7-13.
[4] OSTROM Q T, PATIL N, CIOFFI G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017 [J]. Neuro Oncol, 2020, 22(12 Suppl 2): iv1-iv96.
[5] STUPP R, HEGI M E, MASON W P, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial [J]. Lancet Oncol, 2009, 10(5): 459-66.
[6] JAKOBSSON A, WESTERBERG R, JACOBSSON A. Fatty acid elongases in mammals: their regulation and roles in metabolism [J]. Prog Lipid Res, 2006, 45(3): 237-49.
[7] SASSA T, KIHARA A. Metabolism of very long-chain Fatty acids: genes and pathophysiology [J]. Biomol Ther (Seoul), 2014, 22(2): 83-92.
[8] DEáK F, ANDERSON R E, FESSLER J L, et al. Novel Cellular Functions of Very Long Chain-Fatty Acids: Insight From ELOVL4 Mutations [J]. Front Cell Neurosci, 2019, 13: 428.
[9] XUE X, FENG C Y, HIXSON S M, et al. Characterization of the fatty acyl elongase (elovl) gene family, and hepatic elovl and delta-6 fatty acyl desaturase transcript expression and fatty acid responses to diets containing camelina oil in Atlantic cod (Gadus morhua) [J]. Comp Biochem Physiol B Biochem Mol Biol, 2014, 175: 9-22.
[10] ZHANG Y, PANG S, SUN B, et al. ELOVLs Predict Distinct Prognosis Value and Immunotherapy Efficacy In Patients With Hepatocellular Carcinoma [J]. Front Oncol, 2022, 12: 884066.
[11] QIN L, SONG C Z, YUAN F Y, et al. ELOVL1 is upregulated and promotes tumor growth in hepatocellular carcinoma through regulating PI3K-AKT-mTOR signaling [J]. Heliyon, 2024, 10(15): e34961.
[12] TOMCZAK K, CZERWIŃSKA P, WIZNEROWICZ M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge [J]. Contemp Oncol (Pozn), 2015, 19(1a): A68-77.
[13] ZHAO Z, ZHANG K N, WANG Q, et al. Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients [J]. Genomics Proteomics Bioinformatics, 2021, 19(1): 1-12.
[14] LONSDALE J, THOMAS J, SALVATORE M, et al. The Genotype-Tissue Expression (GTEx) project [J]. Nature Genetics, 2013, 45(6): 580-5.
[15] TANG Z, KANG B, LI C, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis [J]. Nucleic Acids Res, 2019, 47(W1): W556-w60.
[16] PONTéN F, JIRSTRöM K, UHLEN M. The Human Protein Atlas--a tool for pathology [J]. J Pathol, 2008, 216(4): 387-93.
[17] DIGRE A, LINDSKOG C. The Human Protein Atlas-Spatial localization of the human proteome in health and disease [J]. Protein Sci, 2021, 30(1): 218-33.
[18] SZKLARCZYK D, NASTOU K, KOUTROULI M, et al. The STRING database in 2025: protein networks with directionality of regulation [J]. Nucleic Acids Res, 2025, 53(D1): D730-d7.
[19] CHEN B, KHODADOUST M S, LIU C L, et al. Profiling Tumor Infiltrating Immune Cells with CIBERSORT [J]. Methods Mol Biol, 2018, 1711: 243-59.
[20] APPIN C L, BRAT D J. Biomarker-driven diagnosis of diffuse gliomas [J]. Mol Aspects Med, 2015, 45: 87-96.
[21] HUANG B, ZHANG J, ZONG W, et al. Myeloidcells in the immunosuppressive microenvironment in glioblastoma: The characteristics and therapeutic strategies [J]. Front Immunol, 2023, 14: 994698.